LONDON – Cerenis Therapeutics SA is taking a huge bet on a Phase II trial of its recombinant high density lipoprotein (rHDL) product CER-001 in reducing cholesterol, announcing the start of a 500-patient U.S. and European study in patients with acute coronary syndrome. (BioWorld International)

LONDON – Danish vaccines specialist Bavarian Nordic AS is to lead a DKK90 million (US$16.9 million) national project to discover viruses and bacteria that are involved in initiating cancer and which could form the basis of preventative vaccines.